Skip to main content
Premium Trial:

Request an Annual Quote

Sigma-Aldrich Posts 2 Percent Q4 Revenue Growth

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today reported a 2 percent increase in fourth quarter revenues to $582 million, a new quarterly high, but short of analysts' expectations.

The figure for the three months ended Dec. 31, 2010, compares to $573 million for the fourth quarter of 2009. Wall Street expected revenues for the quarter of $587.5 million.

The firm's R&D costs for the fourth quarter increased 6 percent to $17 million from $16 million, while SG&A costs rose 7 percent to $143 million from $134 million a year ago.

Sigma's net income crept up to $94 million, or $0.76 per share, compared to $93 million, $0.75 per share, a year ago. On an adjusted basis, EPS for the quarter was $0.83 per share, compared to $0.80 a year ago. Analysts' estimates were for $0.80 per share.

For full-year 2010, Sigma-Aldrich posted a 6 percent increase in revenues to $2.27 billion from $2.15 billion in 2009, but short of the $2.28 billion expected by Wall Street.

Its R&D costs rose to $66 million for the year, up from $63 million a year ago, and SG&A costs increased to $548 million from $518 million.

Sigma's 2010 net income rose 11 percent to $384 million, or $3.12 per share, from $347 million, or $2.80 per share. On an adjusted basis, EPS was $3.31 for the year, compared to $2.85 a year ago, and above analysts' estimates of $3.29 per share.

As of Dec. 31, Sigma-Aldrich had $569 million in cash and cash equivalents.

For 2011, the firm said that organic sales are expected to grow in the mid-single digit range. Adjusted EPS is expected to be in the range of $3.45 to $3.60.

In a statement, Rakesh Sachdev, President and CEO of Sigma-Aldrich, said, "Market conditions are not likely to change much, so our plans are to continue to execute on our strategic initiatives to drive sales of our analytical, biology, chemistry, and materials science products, to continue the high-single digit organic growth in SAFC, and to enhance our e-commerce and Asia Pacific-Latin American market sales."

In early Wednesday trade on the Nasdaq, shares of Sigma-Aldrich were down 6 percent at $61.61.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.